About that Pfizer vaccine

The analysis was based on 94 cases of COVID-19 among study participants, but Pfizer didn't share an exact breakdown of how many got sick from getting Pfizer's vaccine versus the placebo. The release also didn't specify how many of the cases were severe or mild or if different age groups had varying levels of protection.

Beyond saying there have been no serious safety concerns, Pfizer didn't provide any details on the safety profile, such as the frequency and severity of typical side effects. CEO Albert Bourla said in a statement the company would share additional efficacy and safety data "in the coming weeks."

"This is science by public pronouncement," [William Haseltine, a longtime biotech executive and infectious-disease expert] said.

[...]

Pfizer's news release made no mention of if the vaccine appeared as effective in different subgroups, such as older people, who are more susceptible to the worst outcomes of the virus.

[...]

"It is very welcome news that the vaccine has a measurable effect," Haseltine said, adding there was still much to learn about Pfizer's shot.

[...]

Pfizer's trial, and the ongoing studies of other leading coronavirus-vaccine developers, aren't regularly testing volunteers to gauge asymptomatic infections. That may mean vaccinated people could still become asymptomatic carriers and unknowingly spread the virus to others.

"That's a major point that I don't think most people appreciate," Haseltine said. "It doesn't mean an end to the epidemic."

[...]

"There are many, many outstanding questions which are left unanswered," [Haseltine] added.

[...]

During the pandemic, he has advocated the US to embrace an expansive testing strategy, previously saying the country's response was overly reliant on a vaccine.

  Business Insider

...but hey, do what you want...you will anyway.